Online inquiry

IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4254MR)

This product GTTS-WQ4254MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets Factor VIII substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000132.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2157
UniProt ID P00451
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4254MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9766MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ14111MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ10704MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ1633MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ15084MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ3520MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ5283MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ7980MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GX-H9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW